These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 32165420)

  • 1. Doctor who tried to smuggle ecstasy tablets into UK is struck off while in French prison.
    Dyer C
    BMJ; 2020 Mar; 368():m1048. PubMed ID: 32165420
    [No Abstract]   [Full Text] [Related]  

  • 2. Variability in the 3,4-methylenedioxymethamphetamine content of 'ecstasy' tablets in the UK.
    Wood DM; Stribley V; Dargan PI; Davies S; Holt DW; Ramsey J
    Emerg Med J; 2011 Sep; 28(9):764-5. PubMed ID: 20724467
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of illicit ecstasy tablets: implications for clinical management in the accident and emergency department.
    Sherlock K; Wolff K; Hay AW; Conner M
    J Accid Emerg Med; 1999 May; 16(3):194-7. PubMed ID: 10353046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity.
    Parrott AC
    Psychopharmacology (Berl); 2004 May; 173(3-4):234-41. PubMed ID: 15007594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative determination of 3,4-methylenedioxymethamphetamine by thin-layer chromatography in ecstasy illicit pills in Tehran.
    Shetab Boushehri SV; Tamimi M; Kebriaeezadeh A
    Toxicol Mech Methods; 2009 Nov; 19(9):565-9. PubMed ID: 20047512
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The content of ecstasy tablets: implications for the study of their long-term effects.
    Cole JC; Bailey M; Sumnall HR; Wagstaff GF; King LA
    Addiction; 2002 Dec; 97(12):1531-6. PubMed ID: 12472637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Content of ecstasy in the Netherlands: 1993-2008.
    Vogels N; Brunt TM; Rigter S; van Dijk P; Vervaeke H; Niesink RJ
    Addiction; 2009 Dec; 104(12):2057-66. PubMed ID: 19804461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analytical evidence to show letters impregnated with novel psychoactive substances are a means of getting drugs to inmates within the UK prison service.
    Ford LT; Berg JD
    Ann Clin Biochem; 2018 Nov; 55(6):673-678. PubMed ID: 29534614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Instability of the ecstasy market and a new kid on the block: mephedrone.
    Brunt TM; Poortman A; Niesink RJ; van den Brink W
    J Psychopharmacol; 2011 Nov; 25(11):1543-7. PubMed ID: 20826554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. UK doctor who worked in US after being struck off by GMC has licence withdrawn.
    Dyer C
    BMJ; 2014 Feb; 348():g1613. PubMed ID: 24548845
    [No Abstract]   [Full Text] [Related]  

  • 11. UK doctor is struck off after drug user dies from overmedication.
    Dyer C
    BMJ; 2014 Feb; 348():g1448. PubMed ID: 24513594
    [No Abstract]   [Full Text] [Related]  

  • 12. Impurity profiling of ecstasy tablets seized in Hong Kong by gas chromatography-mass spectrometry.
    Cheng JY; Chan MF; Chan TW; Hung MY
    Forensic Sci Int; 2006 Oct; 162(1-3):87-94. PubMed ID: 16860955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Doctor is struck off for performing liposuction while suspended from UK medical register.
    Dyer C
    BMJ; 2014 Feb; 348():g1655. PubMed ID: 24554187
    [No Abstract]   [Full Text] [Related]  

  • 14. Ecstasy (MDMA, MDA, MDEA, MBDB) consumption, seizures, related offences, prices, dosage levels and deaths in the UK (1994-2003).
    Schifano F; Corkery J; Deluca P; Oyefeso A; Ghodse AH
    J Psychopharmacol; 2006 May; 20(3):456-63. PubMed ID: 16574720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological content of tablets sold as "ecstasy": results from an online testing service.
    Tanner-Smith EE
    Drug Alcohol Depend; 2006 Jul; 83(3):247-54. PubMed ID: 16364567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of a transient instability of the ecstasy market on health concerns and drug use patterns in The Netherlands.
    Brunt TM; Niesink RJ; van den Brink W
    Int J Drug Policy; 2012 Mar; 23(2):134-40. PubMed ID: 21741814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for selective executive function deficits in ecstasy/polydrug users.
    Fisk JE; Montgomery C
    J Psychopharmacol; 2009 Jan; 23(1):40-50. PubMed ID: 18515461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and application of a high-performance liquid chromatography method using monolithic columns for the analysis of ecstasy tablets.
    Mc Fadden K; Gillespie J; Carney B; O'Driscoll D
    J Chromatogr A; 2006 Jul; 1120(1-2):54-60. PubMed ID: 16466734
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The variability of ecstasy tablets composition in Brazil.
    Togni LR; Lanaro R; Resende RR; Costa JL
    J Forensic Sci; 2015 Jan; 60(1):147-51. PubMed ID: 25125149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using Cluster Analysis and ICP-MS to Identify Groups of Ecstasy Tablets in Sao Paulo State, Brazil.
    Maione C; de Oliveira Souza VC; Togni LR; da Costa JL; Campiglia AD; Barbosa F; Barbosa RM
    J Forensic Sci; 2017 Nov; 62(6):1479-1486. PubMed ID: 28205217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.